<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
    </SeriesInfo>
    <SeriesHeader>
      <EditorGroup>
        <Editor AffiliationIDS="Aff1">
          <EditorName DisplayOrder="Western">
            <GivenName>J.M.</GivenName>
            <FamilyName>Walker</FamilyName>
          </EditorName>
        </Editor>
        <Affiliation ID="Aff1">
          <OrgName>School of Life Sciences University of Hertfordshire</OrgName>
          <OrgAddress>
            <City>Hatfield</City>
            <State>Hertfordshire, AL10 9AB</State>
            <Country>UK</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </SeriesHeader>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
        <BookID>978-1-60327-527-9</BookID>
        <BookTitle>T Cell Protocols</BookTitle>
        <BookSubTitle>Second Edition</BookSubTitle>
        <BookVolumeNumber>514</BookVolumeNumber>
        <BookSequenceNumber>514</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-527-9</BookDOI>
        <BookTitleID>145011</BookTitleID>
        <BookPrintISBN>978-1-58829-587-3</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-527-9</BookElectronicISBN>
        <BookChapterCount>11</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="SCL" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="SCL14005" Priority="1" Type="Secondary">Biochemistry, general</BookSubject>
          <BookSubject Code="SCB14000" Priority="2" Type="Secondary">Immunology</BookSubject>
          <BookSubject Code="SCL16020" Priority="3" Type="Secondary">Cell Culture</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor AffiliationIDS="Aff2">
            <EditorName DisplayOrder="Western">
              <GivenName>Gennaro</GivenName>
              <Particle>De</Particle>
              <FamilyName>Libero</FamilyName>
            </EditorName>
            <Role>Dr</Role>
            <Contact>
              <Email>Gennaro.DeLibero@unibas.ch</Email>
            </Contact>
          </Editor>
          <Affiliation ID="Aff2">
            <OrgName>University of Basel</OrgName>
            <OrgAddress>
              <State>Basel</State>
              <Country>Switzerland</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Chapter ID="Chap11" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
          <ChapterID>11</ChapterID>
          <ChapterNumber>Chapter 11</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-527-9_11</ChapterDOI>
          <ChapterSequenceNumber>11</ChapterSequenceNumber>
          <ChapterTitle Language="En">Non-Replicating Recombinant Vaccinia Virus Expressing CD80 to Enhance T-Cell Stimulation</ChapterTitle>
          <ChapterFirstPage>151</ChapterFirstPage>
          <ChapterLastPage>162</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2009</CopyrightYear>
          </ChapterCopyright>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-527-9</BookID>
            <BookTitle>T Cell Protocols</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff3" CorrespondingAffiliationID="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Paul</GivenName>
                <FamilyName>Zajac</FamilyName>
              </AuthorName>
              <Role>PhD</Role>
            </Author>
            <Affiliation ID="Aff3">
              <OrgName>University Hospital Basel, Institute of Surgical Research and Hospital Management</OrgName>
              <OrgAddress>
                <State>Basel</State>
                <Country>Switzerland</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1" Language="En">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">The following method describes the generation of a recombinant vaccinia virus expressing a costimulatory molecule (human CD80 or B7.1).</Para>
            <Para TextBreak="No">The procedure first requires the cloning, by classical methods not described here, of the gene of interest, e.g. CD80, into a vaccinia shuttle plasmid under the control of a virus-specific promoter enabling a transcription during the early phase of infection. Flanking the insert, the plasmid contains viral sequences and a selection maker needed for the insertion into the viral genome. The successive plaque isolation of recombinant virus on cell monolayer described here is based on the transient “gpt” selection system which enables other insertions in different loci of the same virus. Finally, after verification amplification and titration of the recombinant vector, replication will be impaired by a psoralen-UV treatment in order to produce a non-replicating virus. Expression and function of inserts, following infection of cells, are verified by specific phenotypic and functional assays.</Para>
          </Abstract>
          <KeywordGroup Language="En">
            <Heading>Key words</Heading>
            <Keyword>Recombinant vaccinia virus</Keyword>
            <Keyword>vaccine vector</Keyword>
            <Keyword>CTL stimulation</Keyword>
            <Keyword>costimulation</Keyword>
            <Keyword>non-replicating viral vector</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" OutputMedium="Online" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">The induction of specific cytotoxic T lymphocytes (CTL) in vivo requires highly immunogenic vaccine formulation. Therefore, vaccines require adjuvants able to trigger “danger signals” <CitationRef CitationID="CR1">(1)</CitationRef> or able to directly provide immuno-modulators necessary for T-cell stimulation.</Para>
            <Para TextBreak="No">Recombinants vaccinia virus (rVV) are thermostable and relatively easy to produce. In addition, they are endowed with a number of interesting features. First, they can accomodate large inserts, including different genes <CitationRef CitationID="CR2">(2</CitationRef>, <CitationRef CitationID="CR3">3)</CitationRef>. Second, high levels of expression of recombinant proteins can be easily obtained <CitationRef CitationID="CR4">(4)</CitationRef>. Third, integration into the host’s genome does not occur, resulting in high safety of this vector system <CitationRef CitationID="CR5">(5)</CitationRef>. Fourth, rVV was shown to efficiently deliver recombinant epitopes into the class I antigen presentation pathway <CitationRef CitationID="CR6">(6)</CitationRef>. Infection of experimental animals with rVV vectors elicited CTL populations recognizing both VV antigens and peptides encoded by the inserted genes <CitationRef CitationID="CR7">(7)</CitationRef>.</Para>
            <Para TextBreak="No">Prior to any further considerations, we should underline that replicative vaccinia virus handling requires a biosafety level 2 facility. Some countries recommend vaccination of the persons in direct contact with the virus. In order to decrease potential risk of replicating viral vectors in vivo, replication incompetent viruses were developed, including genetically impaired vectors and non-human poxviruses <CitationRef CitationID="CR4">(4)</CitationRef>. Treatment of VV with psoralen and ultraviolet-light irradiation was shown to induce cross-linking of viral DNA and abrogation of cytopathic effect and viral replication. Despite complete inactivation and absence of pathogenicity, high-gene expression following infection with rVV can still be obtained provided that the inserted genes are driven by early promoters <CitationRef CitationID="CR8">(8)</CitationRef>.</Para>
            <Para TextBreak="No">Generation of such viral vectors combining antigens and co-factors <CitationRef CitationID="CR9">(9</CitationRef>, <CitationRef CitationID="CR10">10)</CitationRef> has lead to an increasing number of clinical trial (<Emphasis Type="Italic">see</Emphasis> review by Kaufman <CitationRef CitationID="CR11">(11)</CitationRef>) confirming poxviruses formulation as one of the most effective vaccine formulations for immunotherapeutic approaches currently available.</Para>
          </Section1>
          <Section1 ID="Sec2" OutputMedium="Online">
            <Heading>Materials</Heading>
            <Para TextBreak="No">
              <OrderedList>
                <ListItem>
                  <ItemNumber>1.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">CV-1 cell line : Monkey African Green kidney fibroblast, ATCC CCL70, ECACC No 87032605</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>2.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Vaccinia Virus (wild-type Copenhagen strain obtained from Dr. Drillien Strasbourg, France)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>3.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">cDNA of gene of interest, e.g. human CD80 was obtained from Pr. Dellabona, Milan, Italy)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>4.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Vaccinia shuttle plasmid used here was originally developed and obtained from Dr. Kangla Tsung (San Francisco, CA) and targets insertions in vaccinia A44L locus.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>5.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">LipofectamineTM (Invitrogen, Paisley, UK)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>6.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">OPTI-MEM®I medium (Invitrogen, Carlsbad, CA).</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>7.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">DMEM (and 2× DMEM) + 10% Foetal bovine serum + antibiotic (DMEM-FCS or 2×DMEM)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>8.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Mycophenolic acid (400×): 10 mg/ml in 0.1 N NaOH</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>9.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Xanthine (40×): 10 mg/ml in 0.1 N NaOH</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>10.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Hypoxanthine (400×): 10 mg/ml in H<Subscript>2</Subscript>O</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>11.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Agarose</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>12.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Tris–HCl, 10 and 1 mM, pH 9</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>13.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Sucrose</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>14.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">QIAmp® DNA Blood Mini Kit (Qiagen, Hilden, Germany)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>15.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">PCR reagent</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>16.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Vaccinia specific oligonucleotides</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>17.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Neutral red (10 mg/ml in water)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>18.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Cristal violet solution: 0.1% in 20% ethanol</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>19.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Psoralen (4’-aminomethyl trioxsalen, 100 µg/ml – Calbiochem, LaJolla, CA)</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>20.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Stratalinker + 365 nm bulbs</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>21.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Cup sonicator.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>22.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Human CD80 antibody</Para>
                  </ItemContent>
                </ListItem>
              </OrderedList>
            </Para>
          </Section1>
          <Section1 ID="Sec3" OutputMedium="Online">
            <Heading>Methods</Heading>
            <Section2 ID="Sec4" OutputMedium="Online">
              <Heading>Cloning of Gene of Interest in Vaccinia Shuttle Plasmid</Heading>
              <Para TextBreak="No">The human CD80 cDNA was originally cloned from human PBMC mRNA in a pUC derived plasmid. Using compatible restriction site, the gene was sub-cloned into the plasmid containing sequences from the vaccinia A44L locus (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig11_1_978-1-60327-527-9">
                  <Emphasis Type="Bold">11.1</Emphasis>
                </InternalRef>). Between the two A44L regions, the cloning cassette contains viral early promoters followed by multiple cloning sites followed by a transcriptional termination sequence.
<Figure Category="Standard" Float="Yes" ID="Fig11_1_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 11.1.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Plasmid map of pVVA44L–hCD80.</SimplePara>
                      <SimplePara>Human CD80 cDNA was subcloned, between vaccinia early promoter and termination signal, in the EcoRI site of the cloning cassette which is flanked by sequences from vaccinia A44L locus (for homologous recombination). The primers A44-fwd and A44-rev enabling the amplification of the modified region can also be used for sequencing of the insert.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_11_Fig1_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">Of note this sequence “TTTTTNT” recognized as a stop signal sequence for vaccinia early transcription should not be present in the recombinant gene. In the case of the human CD80 gene, one stop signal was found at position 766 and was modified using the “QuickChange™” Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK).</Para>
            </Section2>
            <Section2 ID="Sec5" OutputMedium="Online">
              <Heading>Infection/Transfection (<Emphasis Type="Italic">see</Emphasis> Note 1)</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">In a 35 mm petri dish, add 5× 10<Superscript>5</Superscript> CV-1 cells in 2 ml DMEM-FCS.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Once the cells are adherent, remove the medium and infect with the wild-type virus at a ratio of 1 pfu (plaque forming unit) for 10–20 cells (MOI of 0.1/0.05) in a total volume of 300 µl PBS.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Gently shake the petri dish in order to cover the monolayer, place it in a 37°C incubator for 1 h (repeat shaking every 15 min).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Forty-five minutes after the infection, prepare the transfection mix (avoid polypropylene plastic tube). In a first tube add 1–2 µg of plasmid to 100 µl OPTI-MEM. In a separate tube, add 10 µl lipofectamine to 100 µl of OPTI-MEM and mix gently with the plasmid suspension.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">After 15 min incubation at room temperature, transfection mix is diluted in 1 ml OPTI-MEM and added onto the infected cells.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The transfected–infected cells are placed back at 37°C for 6–15 h, before adding 1 ml of 10% FCS-DMEM.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The infection is left in the incubator until complete lysis of the monolayer (2–3 days).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Transfer the 2 ml of viral solution and cell debris into a tube and keep at –20°C until the next step.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec6" OutputMedium="Online">
              <Heading>Selection of Recombinant Virus (<Emphasis Type="Italic">see</Emphasis> Notes 2–5)</Heading>
              <Para TextBreak="No">Selection of the recombinant virus is based on <Emphasis Type="Italic">Escherichia coli</Emphasis> guanine phosphoribosyl transferase (gpt) <CitationRef CitationID="CR12">(12)</CitationRef> as a transient marker. In the shuttle plasmid, this “gpt” rescuing gene is located outside of the “stable recombinant zone” between the viral sequences leading to a transient unstable recombinant form. The final selection steps lead to the removal of the selection marker from the final rVV (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig11_2_978-1-60327-527-9">
                  <Emphasis Type="Bold">11.2</Emphasis>
                </InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig11_2_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 11.2.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Principle of transient selection marker for recombinant virus.</SimplePara>
                      <SimplePara>The cloning cassette is flanked by two sequences identical to viral regions (VV1 and VV2) allowing homologous recombinations by genetic crossing-over leading to the insertion of the gene of interest into the wild-type genome of Vaccinia virus.</SimplePara>
                      <SimplePara>During viral replication, a single homologous recombination event, e.g. with the region 1(REC1) generates a recombinant virus containing the entire plasmid whose presence in the viral genome is needed for selection under “pressure” by mycophenolic acid (MPA). However, this intermediate recombinant form contains duplicate sequences and is therefore genetically unstable. Removal of selective pressure will allow the isolation of stable viruses derived from this intermediate form following recombination events either with the two VV1 sequences reverting to the initial form (wt) or, following recombination with the second site (REC2) generating the stable recombinant virus (CD80rVV). The probability of each event is similar, thus the chances of obtaining the wt or the rVV are in theory 50/50.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_11_Fig2_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare one 6-well plate with 5× 10<Superscript>5</Superscript> CV-1 cells per well (in 2 ml DMEM-FCS) and place at 37°C overnight in order to have a confluent monolayer at the time of infection.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Pre-incubate the culture at least 4 h with selective medium : DMEM-FCS + 1/400 MPA + 1/40 xanthine + 1/400 hypoxanthine</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Sonicate the closed tube containing the viral solution in the cup sonicator for 1 min in order to release the virus from intact cells and aggregates.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare tenfold serial dilutions (200 µl in 1,800 µl PBS) until 10<Superscript>−4</Superscript>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Remove the medium from the cells and infect two wells with 200 µl from the dilutions 10<Superscript>−2</Superscript>, 10<Superscript>−3</Superscript> and 10<Superscript>−4</Superscript>. Place at 37°C for 1 h (shake gently every 15 min).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prior to the end of the infection, melt 10 ml of 2% agarose solution and cool it to 45°C in a waterbath.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare 10 ml of 2× selective medium with 2× DMEM-FCS + 50 µl MPA + 500 µl xanthine and 50 µl hypoxanthine. Mix with the 10 ml 45°C agarose just prior the next step</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Remove inoculum from the cells and add 3 ml of agarose-selective medium. Leave at room temperature until solidification then transfer in a CO<Subscript>2</Subscript> incubator at 37°C.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">After 2 days, mark viral plaques by circling (from under) with pen under a reverse microscope. Because the agarose layer may render the identification of viral plaques more difficult, an alternative is to add 2 ml of fresh agarose containing 1/100 of Neutral Red solution which will diffuse and stain (in a few hours) the cell monolayer and leave the plaques unstained. Try to select six plaques in order to have “one clone per well” in the following selection rounds.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>10.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Pick each plaque by “pipetting” the circled zone with sterile filtered tips and transfer into a tube containing 1 ml PBS.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>11.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The following rounds of selection will be performed similarly after sonication of the 1 ml PBS. It is recommended to perform at least two cycles of plaques isolation under selective medium followed by three cycles without pressure (<Emphasis Type="Italic">see</Emphasis>
                        <Emphasis Type="Bold">Note</Emphasis>
                        <Emphasis Type="Bold">6</Emphasis>).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>12.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">After the fifth cycle, perform a last infection with all the clones but under normal DMEM-FCS (no agarose) and leave the infection until complete lysis of the monolayer (2−3 days). The resulting 2 ml of viral solution, transferred in a tube, represents the so-called “mini-amplification” of each clone and will be used to identify the recombinant clones and as “seed” for the generation of larger stocks.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec7" OutputMedium="Online">
              <Heading>Identification of Recombinant Viral Clone</Heading>
              <Para TextBreak="No">In order to verify the identity of the isolated viral clones, PCR is performed on the targeted viral sequences from purified vv genome. Primers specific for the flanking viral sequences are used in order to distinguish the unmodified wild-type vv genome from the insertion−deletion modified locus.<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">vv DNA purification from the clones “mini-amplifications” (as control for the PCR it is recommended to prepare DNA from cells infected with the wild-type virus) is performed by using DNA purification kit (QIAmp® DNA Blood Mini Kit, Qiagen), according to the manufacturer protocol. After thawing and sonication the 2 ml of each viral suspension, 200 µl are transferred in a 1.5 ml tube and mixed together with the lysis buffer and protease. The total DNA is eluted in 100 µl H<Subscript>2</Subscript>O.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Total DNA purified from cells infected with each clone can now be used in a PCR reaction with specific primers for the vaccinia A44L locus :<UnorderedList Mark="Bullet">
                          <ItemContent>
                            <Para TextBreak="No">Total DNA, 5 µl</Para>
                          </ItemContent>
                          <ItemContent>
                            <Para TextBreak="No">Forward primer 5’-gaaagtaaactattatgg-3’ (10 µM), 1 µl</Para>
                          </ItemContent>
                          <ItemContent>
                            <Para TextBreak="No">Reverse primer 5’-gttgaaatctagttctgc-3’ (10 µM), 1 µl</Para>
                          </ItemContent>
                          <ItemContent>
                            <Para TextBreak="No">PCR buffer (10×), 2 µl</Para>
                          </ItemContent>
                          <ItemContent>
                            <Para TextBreak="No">dNTP mix (10 mM), 2 µl</Para>
                          </ItemContent>
                          <ItemContent>
                            <Para TextBreak="No">Taq DNA Pol, 1 µl</Para>
                          </ItemContent>
                          <ItemContent>
                            <Para TextBreak="No">H<Subscript>2</Subscript>O, 8 µl</Para>
                          </ItemContent>
                        </UnorderedList>
                      </Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
                <UnorderedList Mark="None">
                  <ItemContent>
                    <Para TextBreak="No">PCR</Para>
                  </ItemContent>
                  <ItemContent>
                    <Para TextBreak="No">Start : 95°C – 5 min</Para>
                  </ItemContent>
                  <ItemContent>
                    <Para TextBreak="No">Cycle (×30): 95°C – 15 s/56°C – 50 s/72°C – 60 s</Para>
                  </ItemContent>
                  <ItemContent>
                    <Para TextBreak="No">End : 72°C – 5 min/4°C – standby</Para>
                  </ItemContent>
                </UnorderedList>
                <UnorderedList Mark="None">
                  <ItemContent>
                    <Para TextBreak="No">PCR amplicon are analysed on a 1% agarose gel (<Emphasis Type="Bold">Fig.</Emphasis>
                      <InternalRef RefID="Fig11_3_978-1-60327-527-9">
                        <Emphasis Type="Bold">11.3</Emphasis>
                      </InternalRef>).</Para>
                  </ItemContent>
                  <ItemContent>
                    <Para TextBreak="No">Expected size of WT-A44L = 699 bp and of CD80-rVV-A44L =1,233 bp</Para>
                  </ItemContent>
                </UnorderedList>
                <Figure Category="Standard" Float="Yes" ID="Fig11_3_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 11.3.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Gel electrophoresis of PCR amplicons from A44L locus from VV genome.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_11_Fig3_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">Make sure that no wild-type band appears in the selected recombinant clone as this may be a sign of viral mixture requiring further plaque isolation cycles.</Para>
              <Para TextBreak="No">Moreover, to verify that the genome of the rVV clone does not contain anymore the resistance gene one can perform a comparative infection with and without selective medium. Plaques should only appear in infection without MPA.</Para>
            </Section2>
            <Section2 ID="Sec8" OutputMedium="Online">
              <Heading>Amplification and Concentration of rVV</Heading>
              <Para TextBreak="No">The selected recombinant clone mini-amplification can now serve as “seed” to generate stocks of concentrated virus. The purification procedure is based on the increased density of concentrated sucrose solutions prepared in Tris 10 mM (weight/volume) and sterilized by filtration.<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare ten sub-confluent flasks (175 cm<Superscript>2</Superscript>) of CV-1 cells</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Infect with the selected rVV clone. Dilute 100 µl of the seed virus in 10 ml of PBS and directly add 1 ml in the culture medium of each flask.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Leave at 37°C until cytopathogenic effect (CPE) is complete (usually 3–4 days)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Detach the infected cells with one cycle of freeze–thaw and pool the cells by centrifugation (2,000 rpm 3 min) in a 50-ml tube. Pool and save the supernatants.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Resuspend the cell pellet in 10 ml Tris 10 mM and sonicate for 2 min. Centrifuge at 2,000 rpm for 3 min and transfer the supernatant in a fresh tube.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">This step can be repeated a second time.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare 15 ml of a 36% sucrose cushion in polyallomer ultra-centrifuge tubes for SW-27 rotor (Beckman Coulter, Fullerton, CA), and overlay with 20 ml of viral supernatant (alternatively one can underlay the sucrose below the supernatant).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Centrifuge at 30,000 × <Emphasis Type="Italic">g</Emphasis> (13,000 rpm) for 90 min and resuspended the pellets in 3–5 ml Tris 1 mM.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">This semi-purified viral solution can either be aliquoted and stored at –20°C or further purified on a sucrose gradient.<OrderedList>
                          <ListItem>
                            <ItemNumber>a.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">In a SW-27 centrifuge tube, prepare a sucrose gradient by carefully overlaying 6 ml of sucrose 40, 36, 32, 28 and 24% before adding the virus and centrifuge at 26,000 <Emphasis Type="Italic">g</Emphasis> for 45 min.</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>b.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Collect the viral band in the middle of the continuous gradient established during centrifugation.</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>c.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Resuspend in 30–35 ml (final volume) with Tris 1 mM and pellet in a SW-27 sterile tube, by centrifugation at 30,000 <Emphasis Type="Italic">g</Emphasis> for 60 min.</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>d.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Collect the viral pellet with 2 ml Tris 1 mM and aliquot in freezing tubes.</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>e.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Store at –70°C (stocks) and keep one aliquot for the next steps.</Para>
                            </ItemContent>
                          </ListItem>
                        </OrderedList>
                      </Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec9" OutputMedium="Online">
              <Heading>Titration of rVV</Heading>
              <Para TextBreak="No">Titer of virus is expressed as “plaque forming unit per millilitre of solution” = pfu/ml<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare one 6-well plate of confluent CV-1 cells.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare a tenfold serial dilution in PBS of the sonicated stock virus until dilution 10<Superscript>−8</Superscript> (100 µl in 900 µl PBS).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Remove medium from culture (leaving about 200 µl).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Add 100 µl of dilutions 10<Superscript>−6</Superscript>, 10<Superscript>−7</Superscript> and 10<Superscript>−8</Superscript> in two wells.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Incubate at 37°C for 1 h with gentle agitation every 15 min.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Add 2 ml of medium and incubate 2 days at 37°C.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Replace the medium with 300 µl of crystal violet for 2 min.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Remove the staining solution and count the plaques.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
              <Para TextBreak="No">Calculate the concentration of the viral stock based on sufficient number of plaques (avoid to use dilutions giving less than ten plaques): For instance, if 63 and 57 plaques were counted at dilution 10<Superscript>−7</Superscript>, the average of 60 should be multiplied by 10<Superscript>7</Superscript> (the dilution factor) and the by 10 (since 100 µl were used for infection). The resulting titer is 6×10<Superscript>9</Superscript> pfu/ml</Para>
            </Section2>
            <Section2 ID="Sec10" OutputMedium="Online">
              <Heading>Inactivation of rVV (<Emphasis Type="Italic">see</Emphasis> Notes 7 and 8)</Heading>
              <Para TextBreak="No">Inactivation of viral replication generates a completely safe vector for research and clinical applications <CitationRef CitationID="CR8">(8</CitationRef>, <CitationRef CitationID="CR13">13)</CitationRef>. Furthermore, this type of inactivated vector remains also “non-cytopathic” and most infected cells (at MOI below 10) can survive with no apparent negative effect. The technique used here is based on the random cross-linking of the genomic DNA of the virus with psoralen and long-wave UV. The resulting cross linking should be sufficient to abolish any possible replication but should also still enable early transcription which does not depend from the viral replication (as opposed to late viral protein).<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Dilute the virus to a concentration of 5×10<Superscript>8</Superscript> PFU/ml in 1 ml of Hanks’ Balanced Salts Solution (Invitrogen, Carlsbad, CA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Add 10 µl of psoralen (100 µg/ml) and incubate 10 min at room temperature.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Transfer the solution in a 35-mm dish and place in the stratalinker (Stratagene, LaJolla, CA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Remove the cover and irradiate with 365 nm UV light for 10 min (1.6 J)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Aliquot in 250 µl vials and freeze at −20°C</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec11" OutputMedium="Online">
              <Heading>Expression of Recombinant Genes</Heading>
              <Para TextBreak="No">The final verification of the construction of a recombinant virus is the characterization of the expression of the recombinant protein. In the case of the human CD80 costimulatory molecule, a simple antibody staining of the surface of infected cells will be sufficient to assess the presence of the new molecule.<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Prepare a 6-well plate with 10<Superscript>6</Superscript> CV1 per well.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Perform the infection with control virus and CD80rVV inactivated viruses at MOI 10 (thus 10<Superscript>7</Superscript> pfu) following the same procedure as described before (leave a non-infected control)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Incubate from 6 to 24 h (for an easier detection, leave at least overnight)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Trypsinize the infected cells and transfer into FACS tube. Wash with PBS (add 2 ml of PBS, centrifuge 1,300 rpm for 2 min and decant supernatant)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Incubate for 30 min at 4°C with fluorescent-labelled specific human CD80 antibody or an isotype matched control reagent.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Wash twice with PBS and resuspend in 1 ml of fixing solution (4% paraformaldehyde ) for 10 min.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Centrifuge 2 min at 1,500 rpm, decant the supernatant and resuspend in 300–500 µl PBS.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Acquire the cells with a FACS instrument.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
              <Para TextBreak="No">Compared to the replicative counterpart virus, the characteristic expression from a virus inactivated with psoralen-UV usually displays a negative cell population resulting from infection with virus containing “cross-linked” gene thus unable to be transcribed. The frequency of “hits” in a gene is proportional to its length. However, as early transcription is no longer shut-off upon replication, the intensity of expression of an intact early gene is stronger as compared to its expression from a replicative recombinant virus (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig11_4_978-1-60327-527-9">
                  <Emphasis Type="Bold">11.4</Emphasis>
                </InternalRef>).
<Figure Category="Standard" Float="Yes" ID="Fig11_4_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 11.4.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Expression of human CD80 molecules from CD80rVV infected cells.</SimplePara>
                      <SimplePara>Expression of human CD80 as detected by specific antibody staining and FACS analysis. CV-1 cells were infected with (<Emphasis Type="Bold">A</Emphasis>) replicative and (<Emphasis Type="Bold">B</Emphasis>) inactivated virus (MOI 10). The <Emphasis Type="Italic">thin line</Emphasis> represents the staining of a negative control infection with wild-type virus.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_11_Fig4_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">The use of CD80rVV during CTL stimulation in vitro and in vivo has demonstrated an increase capacity to activate CD8+ cells <CitationRef CitationID="CR14">(14</CitationRef>, <CitationRef CitationID="CR10">10)</CitationRef>.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec12" OutputMedium="Online">
            <Heading>Notes</Heading>
            <Para TextBreak="No">
              <OrderedList>
                <ListItem>
                  <ItemNumber>1.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">This step is crucial for the efficiency of the following selection. Pay attention to the cells “quality” and perform, as described, a low moi infection.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>2.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">After infection, cell-culture medium with only 5% FCS can be used instead of 10%.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>3.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Make sure your selective media is efficient by inhibiting the formation of plaques from a wild-type virus infection.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>4.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Make sure to select “real” replicative plaque especially at the very first cycle under pressure. Indeed, at this step there should be more than 10,000 wild-type virus for a single recombinant event. At this dose, even under pressure, wild-type virus can create some false small “starting plaques” resulting from the ECP of toxic effect of high-dose virus.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>5.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">One can keep each cycle of selection at −20°C until the final selection in order to avoid to restart from the beginning in case of a problem with a cycle.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>6.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">It is also recommended to select two plaques from each clone at the second isolation step without pressure in order to reach about a dozen of separate clones. Indeed each plaque selected after the first cycle without pressure contains a mixture of each possible forms of virus. Increasing the number of clones and passage increases the chance of isolating the recombinant form with no contamination with the other forms (intermediate and wt).</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>7.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">The level of inactivation of the virus may vary depending on the efficiency of the chemical solution and most of all, on the “age” of the UV bulbs. Thus it is recommended to evaluate the inactivation of virus by performing infections at different MOI. On CV-1 cells, correctly inactivated virus should display no major CPE before MOI of 15–20. But rec. virus should not be “over-inactivated” and verification of expression should also be performed in order to validate the procedure of inactivation.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>8.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Batches of virus are usually very stable at −70°C but one should avoid repeated freeze–thaw (more than three times) of each aliquot of inactivated virus as expression may strongly decrease.</Para>
                  </ItemContent>
                </ListItem>
              </OrderedList>
            </Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-527-9_Chapter_11.pdf" OutputMedium="All" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Matzinger</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The danger model: a renewed sense of self</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>296</VolumeID>
                <FirstPage>301</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjtVWiurk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1071059</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>11951032</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR2">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ.</Initials>
                  <FamilyName>Goebel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP.</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME.</Initials>
                  <FamilyName>Perkus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SW.</Initials>
                  <FamilyName>Davis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP.</Initials>
                  <FamilyName>Winslow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E.</Initials>
                  <FamilyName>Paoletti</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">The complete DNA sequence of vaccinia virus</ArticleTitle>
                <JournalTitle>Virology</JournalTitle>
                <VolumeID>179</VolumeID>
                <FirstPage>247</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXhtFKjuro%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0042-6822(90)90294-2</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>2219722</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. Virology 1990;179:247–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR3">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GP.</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ.</Initials>
                  <FamilyName>Goebel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E.</Initials>
                  <FamilyName>Paoletti</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">An update on the vaccinia virus genome</ArticleTitle>
                <JournalTitle>Virology</JournalTitle>
                <VolumeID>196</VolumeID>
                <FirstPage>381</FirstPage>
                <LastPage>401</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXmsVaisbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1006/viro.1993.1494</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8372428</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Johnson GP, Goebel SJ, Paoletti E. An update on the vaccinia virus genome. Virology 1993;196:381–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR4">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B.</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>11341</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xmtlagsrw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.93.21.11341</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8876137</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR5">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B.</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Poxvirus vectors: cytoplasmic expression of transferred genes</ArticleTitle>
                <JournalTitle>Curr Opin Genet Dev</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>86</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXkt1Wgtrw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0959-437X(05)80346-6</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8453278</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moss B. Poxvirus vectors: cytoplasmic expression of transferred genes. Curr Opin Genet Dev 1993;3:86–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR6">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR.</Initials>
                  <FamilyName>Bennink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW.</Initials>
                  <FamilyName>Yewdell</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function</ArticleTitle>
                <JournalTitle>Curr Top Microbiol Immunol</JournalTitle>
                <VolumeID>163</VolumeID>
                <FirstPage>153</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M%2FlsFCrtg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>2242679</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bennink JR, Yewdell JW. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Top Microbiol Immunol 1990;163:153–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR7">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR.</Initials>
                  <FamilyName>Bennink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW.</Initials>
                  <FamilyName>Yewdell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL.</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C.</Initials>
                  <FamilyName>Moller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B.</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>311</VolumeID>
                <FirstPage>578</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXmt1ektbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/311578a0</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>6332992</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 1984;311:578–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR8">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K.</Initials>
                  <FamilyName>Tsung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH.</Initials>
                  <FamilyName>Yim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Marti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM.</Initials>
                  <FamilyName>Buller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA.</Initials>
                  <FamilyName>Norton</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light</ArticleTitle>
                <JournalTitle>J Virol</JournalTitle>
                <VolumeID>70</VolumeID>
                <FirstPage>165</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXpvFSnu7s%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8523521</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tsung K, Yim JH, Marti W, Buller RM, Norton JA. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol 1996;70:165–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR9">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J.</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW.</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The diversity of T-cell co-stimulation in the induction of antitumor immunity</ArticleTitle>
                <JournalTitle>Immunol Rev</JournalTitle>
                <VolumeID>170</VolumeID>
                <FirstPage>73</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXntlCrsrs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1600-065X.1999.tb01330.x</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>10566143</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schlom J, Hodge JW. The diversity of T-cell co-stimulation in the induction of antitumor immunity. Immunol Rev 1999;170:73–84</BibUnstructured>
            </Citation>
            <Citation ID="CR10">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Zajac</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Schutz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D.</Initials>
                  <FamilyName>Oertli</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>4567</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmslWrs70%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9788602</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zajac P, Schutz A, Oertli D, et al. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res 1998;58:4567–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR11">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL.</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The role of poxviruses in tumor immunotherapy</ArticleTitle>
                <JournalTitle>Surgery</JournalTitle>
                <VolumeID>134</VolumeID>
                <FirstPage>731</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0039-6060(03)00294-0</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>14639347</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kaufman HL. The role of poxviruses in tumor immunotherapy. Surgery 2003;134:731–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR12">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FG.</Initials>
                  <FamilyName>Falkner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B.</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Transient dominant selection of recombinant vaccinia viruses</ArticleTitle>
                <JournalTitle>J Virol</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>3108</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXktVWmsbw%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>2159565</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Falkner FG, Moss B. Transient dominant selection of recombinant vaccinia viruses. J Virol 1990;64:3108–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR13">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Zajac</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D.</Initials>
                  <FamilyName>Oertli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Marti</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients</ArticleTitle>
                <JournalTitle>Hum Gene Ther</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1497</FirstPage>
                <LastPage>510</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXotlejt70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1089/104303403322495016</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>14577912</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zajac P, Oertli D, Marti W, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003;14:1497–510.</BibUnstructured>
            </Citation>
            <Citation ID="CR14">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WR.</Initials>
                  <FamilyName>Marti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Zajac</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G.</Initials>
                  <FamilyName>Spagnoli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Heberer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D.</Initials>
                  <FamilyName>Oertli</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro</ArticleTitle>
                <JournalTitle>Cell Immunol</JournalTitle>
                <VolumeID>179</VolumeID>
                <FirstPage>146</FirstPage>
                <LastPage>152</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmtlOgs74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1006/cimm.1997.1158</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9268498</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marti WR, Zajac P, Spagnoli G, Heberer M, Oertli D. Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro. Cell Immunol 1997;179:146–152.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Book>
  </Series>
</Publisher>
